VANCOUVER, Jan. 14, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Andrew Riseman Ph.D. effective January 11, 2013. Dr. Riseman will be assisting the Company in Applied Biology and Plant Sciences.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to have Dr. Riseman join our Abattis team. His expertise in tissue and plant breeding sciences will be a tremendous asset to Abattis; we will apply his knowledge to produce proprietary intellectual property for the company. "
Andrew Riseman Ph.D., Associate Professor, Plant Biology and Plant Breeding at UBC stated, I am very excited about this opportunity to work with such a great company to advance botanical sciences in the Medical Marijuana and other medicinal plant breeding sciences, I see Abattis a company with the ability to engineer, grow and extract advanced Pharmaceutical Grade Compounds "PGC's" that ensure traceability, consistency in dosing and safety with a target to produce the purest compounds from chosen cultivars."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
|Michael Withrow, President & CEO|
Neither the CNSX Exchange nor its regulations services accepts
for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.